These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 15621667)
1. Prophylactic role of immunomodulators in treatment of systemic candidiasis in leukopenic mice. Khan MA; Firoz A; Jabeen R; Mohammad O J Drug Target; 2004; 12(7):425-33. PubMed ID: 15621667 [TBL] [Abstract][Full Text] [Related]
2. Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. Khan MA; Nasti TH; Saima K; Mallick AI; Firoz A; Wajahul H; Ahmad N; Mohammad O FEMS Immunol Med Microbiol; 2004 Jul; 41(3):249-58. PubMed ID: 15196575 [TBL] [Abstract][Full Text] [Related]
3. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. Khan MA; Syed FM; Nasti HT; Saima Dagger K; Haq W; Shehbaz A; Owais M J Drug Target; 2003 Feb; 11(2):93-9. PubMed ID: 12881195 [TBL] [Abstract][Full Text] [Related]
4. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice. Khan MA; Khan A; Owais M FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598 [TBL] [Abstract][Full Text] [Related]
5. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis. Masood AK; Faisal SM; Haque W; Owais M J Drug Target; 2002 May; 10(3):185-92. PubMed ID: 12075819 [TBL] [Abstract][Full Text] [Related]
6. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B. Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448 [TBL] [Abstract][Full Text] [Related]
7. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. Khan MA; Nasti TH; Owais M J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780 [TBL] [Abstract][Full Text] [Related]
8. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
9. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice. Khan MA; Owais M J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211 [TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model. Khan MA; Faisal SM; Mohammad O J Drug Target; 2006 May; 14(4):233-41. PubMed ID: 16777682 [TBL] [Abstract][Full Text] [Related]
12. Immune stimulating and therapeutic potential of tuftsin-incorporated nystatin liposomes against Cryptococcus neoformans in leukopenic BALB/C mice. Khan MA; Aljarbou A; Khan A; Owais M FEMS Immunol Med Microbiol; 2012 Oct; 66(1):88-97. PubMed ID: 22612788 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis. Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705 [TBL] [Abstract][Full Text] [Related]
14. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.]. Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489 [TBL] [Abstract][Full Text] [Related]
15. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice. van Etten EW; Snijders SV; van Vianen W; Bakker-Woudenberg IA Antimicrob Agents Chemother; 1998 Sep; 42(9):2431-3. PubMed ID: 9736577 [TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso). Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Takemoto K; Yamamoto Y; Ueda Y Microbiol Immunol; 2006; 50(8):579-86. PubMed ID: 16924142 [TBL] [Abstract][Full Text] [Related]
18. Betamethasone augments the antifungal effect of menadione--towards a novel anti-Candida albicans combination therapy. Jakab Á; Emri T; Sipos L; Kiss Á; Kovács R; Dombrádi V; Kemény-Beke Á; Balla J; Majoros L; Pócsi I J Basic Microbiol; 2015 Aug; 55(8):973-81. PubMed ID: 25707543 [TBL] [Abstract][Full Text] [Related]
19. [Investigation of quantitative and species composition and antifungal drug susceptibility of yeasts isolated from patients with generalized periodontitis complicated by candidosis]. Kutsyk RV; Pavliuk TD Mikrobiol Z; 2003; 65(5):26-9. PubMed ID: 14723159 [TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility and resistance of Candida spp. to hamycin. Athar MA Sabouraudia; 1971 Nov; 9(3):256-62. PubMed ID: 4944203 [No Abstract] [Full Text] [Related] [Next] [New Search]